Compensated Awareness Post View
Disclaimer
Cumberland Pharmaceuticals, Inc. (CPIX) Building Shareholder Value with Five Commercial Products and Strong Development Pipeline
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The company’s product portfolio currently features five marketed treatments – including Acetadote®, Caldolor®, Kristalose®, Vaprisol® and Omeclamox-Pak® – addressing its primary target markets of hospital acute care and gastroenterology. Cumberland owns the worldwide rights to all of its brands, allowing the company to focus on the U.S. market while actively pursuing strategic partnerships and other opportunities to make its products available to patients in underserved international markets.
In the second quarter of 2015, Cumberland’s strongest performing product was Kristalose, which accounted for $4.1 million in net revenue. As the only branded prescription laxative product that features the established safety and efficacy of lactulose in a pre-measured powder dose, Kristalose offers patients a virtually tasteless, grit-free and essentially calorie-free alternative to lactulose syrups. In a 2009 study by Clinical and Experimental Gastroenterology, the company’s product was preferred by 83 percent of patients, highlighting the immense market potential of Cumberland’s product portfolio moving forward.
In addition to its commercialized products, Cumberland is currently engaged in late-stage clinical development of two promising drug candidates. Hepatoren® is being developed to treat patients suffering from hepatorenal syndrome, while Boxaban® is being developed for the treatment of aspirin-exacerbated respiratory disease. Enrollment for phase II studies of both candidates is underway and expected to be completed by the end of 2015. To ensure reliable expansion of its product portfolio in the future, Cumberland also operates Cumberland Emerging Technologies (CET), which, in collaboration with some of the country’s top universities, is providing the company with a long-term pipeline of new product candidates.
As of June 30, 2015, Cumberland reported approximately $93 million in total assets, including $53 million in cash and investments, with only $14.2 million in total liabilities. In the coming months, the company will look to leverage the flexibility offered by this balance sheet to promote long-term, sustainable growth.
“We remain in a strong financial position with a solid balance sheet and profitable operations,” A.J. Kazimi, chief executive officer of Cumberland, stated in a news release. “We are working to maximize the potential of our five commercial products and actively pursuing the addition of new brands to our portfolio.”
With an established product portfolio, a promising development pipeline and a steady supply of new candidates provided by CET, Cumberland is in a strong strategic position to expand upon its considerable industry presence in the years to come. For prospective shareholders, the company’s favorable balance sheet and persistent commitment to expanding upon its market share could foreshadow an opportunity for Cumberland to achieve sustainable returns for the foreseeable future.
For more information, visit www.cumberlandpharma.com
